A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Inclusion Criteria

• Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per the Revised European-American Lymphoma World Health Organization (WHO) 2016 classification

• The following non-sALCL PTCL subtypes are eligible:

  • PTCL - not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1)
  • Enteropathy-associated T-cell lymphoma (EATL)
  • Hepatosplenic T-cell lymphoma
  • Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)
  • Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract
  • Follicular T-cell lymphoma
  • Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype
• CD30 expression <10% by local assessment
• Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist
• An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

Exclusion Criteria

• Current diagnosis of any of the following:

  • sALCL
  • Primary cutaneous T-cell lymphoproliferative disorders and lymphomas
  • Mycosis fungoides (MF), including transformed MF
• History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ≥90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
• History of progressive multifocal leukoencephalopathy (PML).
• Cerebral/meningeal disease related to the underlying malignancy.
• Prior treatment with brentuximab vedotin.
• Baseline peripheral neuropathy Grade 2 or higher (per the NCI CTCAE, Version 4.03) or subjects with the demyelinating form of Charcot-Marie-Tooth syndrome.
• Left ventricular ejection fraction less than 45% or symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), or myocardial infarction within the past 6 months, or previous treatment with complete cumulative dose of >300 mg/m2 of doxorubicin.
• Any uncontrolled Grade 3 or higher (per the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted.